AsclepiX Therapeutics, Inc.
Bethesda, US · Founded 2023 · Delaware corporation · 1 known investors
Biopharmaceutical company using computational biology to identify and develop novel peptide therapies, including AXT107 for retinal/eye diseases.
Founders & leadership
AsclepiX Therapeutics, Inc. was founded in 2023 by Aleksander S. Popel, PhD and Jordan J. Green.
AS
Aleksander S. Popel, PhDCo-founder
JJ
Jordan J. GreenCo-founder
WP
Wendy PerrowExecutive
Investors · 1
Reported raises · per SEC filings
Form D private placements$28M disclosed across 4 rounds · 2017–2023
▶$10MraisedApr 2024 · 9 investors · BiotechnologyRule 506(b)
▶$10MraisedApr 2024 · 9 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Robert DempseyExecutive Officer
- Steven AltschulerDirector
- Ben AskewDirector
- Josh BarerDirector
- Chris GarabedianDirector
- Aleksander PopelExecutive Officer
- Sapna SrivastavaDirector
- Amir ShojaeiExecutive Officer
- Niranjan PandeyExecutive Officer
- Jill TierneyExecutive Officer
- Jordan GreenDirector
- Offering amount
- $12.5M
- Amount sold
- $10M
- First sale
- Jul 2023
- Incorporated
- Corporation, Delaware, 2023
- Federal exemptions
- 06b
▶$10MraisedJun 2020 · 34 investors · BiotechnologyRule 506(b)
▶$10MraisedJun 2020 · 34 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Sapna SrivastavaDirector
- Aleksander S. Popel, PhDDirector
- Jordan J. GreenDirector
- Kevin Slawin, MDExecutive Officer, Director
- Steven Altschuler, MDDirector
- Joshua BarerDirector
- Offering amount
- $35M
- Amount sold
- $10M
- First sale
- May 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$7.7MraisedJun 2019 · 26 investors · BiotechnologyRule 506(b)
▶$7.7MraisedJun 2019 · 26 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Steven Altschuler, MDDirector
- Sapna SrivastavaDirector
- Joshua BarerDirector
- Kevin Slawin, MDDirector
- Aleksander S. Popel, PhDDirector
- Wendy PerrowExecutive Officer, Director
- Jordan J. GreenDirector
- Offering amount
- $10M
- Amount sold
- $7.7M
- Sales commissions
- $40K
- Proceeds to insiders
- $575K
- Placement agents
- Solebury Capital LLC
- First sale
- Oct 2018
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$175KraisedFeb 2017 · 5 investors · BiotechnologyRule 506(b)
▶$175KraisedFeb 2017 · 5 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Aleksander S. Popel, PhDExecutive Officer, Director
- Jordan J. GreenExecutive Officer, Director
- Wendy PerrowExecutive Officer, Director
- Offering amount
- $1M
- Amount sold
- $175K
- First sale
- Feb 2017
- Incorporated
- Limited Liability Company, Maryland
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Non-dilutive funding · 6 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2019 | $299.8K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2018 | $300K |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2017 | $2.1M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2015 | $278.1K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2014 | $260.6K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2014 | $258K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
Frequently asked questions
- What does AsclepiX Therapeutics, Inc. do?
- Biopharmaceutical company using computational biology to identify and develop novel peptide therapies, including AXT107 for retinal/eye diseases.
- Who founded AsclepiX Therapeutics, Inc.?
- AsclepiX Therapeutics, Inc. was founded by Aleksander S. Popel, PhD, Jordan J. Green in 2023.
- Who are AsclepiX Therapeutics, Inc.'s investors?
- AsclepiX Therapeutics, Inc.'s investors include Rapha Capital Management, LLC.
- How much funding has AsclepiX Therapeutics, Inc. raised?
- AsclepiX Therapeutics, Inc. has disclosed $28M raised across 4 rounds.
- Where is AsclepiX Therapeutics, Inc. headquartered?
- AsclepiX Therapeutics, Inc. is headquartered in Bethesda, US.